DVAX — Dynavax Technologies Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corporation (DVAX) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Ryan Spencer, based in 2100 Powell Street, EmeryVille, CA, United States, 94608, with about 405 employees. Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
Latest reported DVAX revenue for 2025-09-30 was $94.9M. Net income was $26.9M. Revenue was down 0.6% from 2025-06-30 to 2025-09-30. DVAX currently screens at market cap $1.82B.
Use this DVAX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DVAX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DVAX SEC filings page. Lician reads the product cache first so this HTML stays unique to Dynavax Technologies Corporation even when a live quote feed is slow.
About Dynavax Technologies Corporation
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccine candidate in Phase 1/2 clinical trial for the prevention of shingles in adults aged 50 years and older, as well as HEPLISAV-B for adults on hemodialysis. The company sells its products to hospitals and clinics, integrated delivery networks, public health clinics and prisons, the Department of Defense, the Department of Veterans Affairs, and retail pharmacies through wholesalers and specialty distributors. It has a collaboration agreement with the U.S. Department of Defense; Coalition for Epidemic Preparedness Innovations; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; and Biological E. Limited. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.
DVAX Key Statistics
Market Cap
$1.82B
P/B Ratio
3.30
EPS
$0.20
Revenue
$277.25M
Net Income
$27.31M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+19.4%
Profit Margin
9.9%
Employees
405
DVAX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $277.25M | $232.28M | $722.68M | $439.44M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $27.31M | -$6.39M | $293.16M | $76.71M |
| EPS (Diluted) | $0.20 | -$0.05 | $1.97 | $0.57 |
Total Assets
$986.26M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$95.88M
Operating Cash Flow
$66.51M
Free Cash Flow
$0.00
Dynavax Technologies Corporation Company Information
- CEO & Director
- Ryan Spencer
- Headquarters
- 2100 Powell Street, EmeryVille, CA, United States, 94608
- Website
- www.dynavax.com
- Phone
- 510 848 5100
- IPO / Founded
- 2004-02-19
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic